Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance
Mogrify, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has launched EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion. EpiMOGRIFY is an extension of […]
